B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12
B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.
Stocks · News reference
8-K filing — Candel Therapeutics, Inc. (CADL)
Filed: 2026-09-10 AccNo: 0001193125-26-387310 Size: 231 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.
Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over losses of $(0.09) per